Sorrento Therapeutics Inc SRNE

Healthcare Biotechnology

Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune diseases and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. The Sorrento Therapeutics segment is organized around its Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate the next-generation of cancer therapeutics. The Scilex segment is organized around its non-opioid pain management operations and clinical pipeline. The Company’s immuno-oncology platforms, including its fully human antibodies (G-MAB library), ACEA small molecule library, immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs) and oncolytic virus (Seprehvec). The Company is also developing potential antiviral therapies against COVID-19, including FUJOVEE (Abivertinib) and its rapid diagnostic test, including COVIMARK.

GREY:SRNE - Post by User

Sorrento Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by TheeRookon Jun 23, 2021 3:29am

322 Views

Post# 33432768

No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19

Interesting

Sorrento Enters Into Multi-Year Cooperative Research and Development Agreement With the U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) For Pandemic Preparedness Combating COVID-19

Broad multi-year agreement between Sorrento Therapeutics and U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp Lemonnier, Djibouti, and Accra, Ghana.
Scope includes infectious diseases research and development, product validation, and disease surveillance to inform public health policy of host nation partners, and to improve medical readiness of the U.S. Armed Forces for NAMRU-3 areas of responsibility (U.S. European Command, U.S. Central Command, U.S. Africa Command)
Initial focus of the collaboration is to improve infectious disease readiness through surveillance and clinical diagnostic validation activities for COVISTIX/COVITRACK Diagnostic Tests and COVIDROPS/COVI-AMG neutralizing antibody treatments for COVID-19 patients.